Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
cixutumumab insulin-like growth factor i receptor NA Successful target TTD , DGIDB Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of liver[MeSHID:D008113]		 5.03 phase 2 unknown
cixutumumab insulin-like growth factor i receptor NA Successful target TTD , DGIDB Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of liver[MeSHID:D008113]		 5.03 phase 2 antagonist
cixutumumab insulin-like growth factor 1 receptor biotech NA drugbank , DGIDB Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of liver[MeSHID:D008113]		 5.03 investigational antagonist
cixutumumab insulin-like growth factor 1 receptor biotech NA drugbank , DGIDB Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of liver[MeSHID:D008113]		 5.03 investigational antibody
cixutumumab insulin-like growth factor 1 receptor biotech NA drugbank , DGIDB Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of liver[MeSHID:D008113]		 5.03 investigational unknown
cixutumumab insulin-like growth factor i receptor NA Successful target TTD , DGIDB Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant neoplasm of liver[MeSHID:D008113]		 5.03 phase 2 antibody
click here to return to the previous page